Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation
Translation Control Discovery Platform
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
• Analysis Assessment
• Bio Data Analysis
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact firstname.lastname@example.org.
17 Scientific Collaborations
Eur J Cell Biol (2018) ; 97 : 168-179.
Integr Biol (2016); 8 :645-53
J Cell Biol. 2016; 23;213(4):451-62.
Nucleic Acid Res. (2017); 45 :926-937
News & Events
2019 BIO International Convention
When: Jun. 3rd, 2019 - Jun. 6th, 2019
Where: Philadelphia, USA
Anima Biotech has been invited to present an overview of its business and strategy during the 2019 BIO International Convention.
The BIO International Convention is packed with the latest trends, technologies, companies and breakthrough ideas in biotech and pharma. The convention now boasts more than 1,800 exhibiting companies and delegations from 67 countries and hosts a variety of activities and provides opportunities to learn more about how attendees can help fuel the next big breakthrough.
European High Content Screening User Group Meeting
When: May. 16th, 2019 - May. 17th, 2019
Where: Barcelona, Spain
Anima Biotech has been invited to present about the discovery of Protein Synthesis Modulators of "Undruggable" Targets using its Translation Control Therapeutics platform during the European High Content Screening User Group Meeting 2019.
The European High Content Screening User Group Meeting provides a unique opportunity for users to appreciate the broad diversity of HCS applications; gain insights into new workflow solutions; share their experience, discuss challenges and learn about technology updates.
11th Annual International ChinaBio Partnering Forum 2019
When: May. 8th, 2019 - May. 9th, 2019
Where: Shanghai, China
Anima Biotech has been invited to present about its business, technology and partnering strategies during the 11thAnnual International ChinaBio Partnering Forum 2019.
The ChinaBio Partnering Forum is the premier life science partnering event in China. The event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.